---
title: "OLSI.US (OLSI.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/OLSI.US/news.md"
symbol: "OLSI.US"
name: "OLSI.US"
parent: "https://longbridge.com/zh-CN/quote/OLSI.US.md"
datetime: "2026-03-16T08:20:18.912Z"
locales:
  - [en](https://longbridge.com/en/quote/OLSI.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OLSI.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OLSI.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/OLSI.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/OLSI.US/news.md)


# OLSI.US (OLSI.US) — 相关新闻

### [BioSyent Inc. completes acquisition of Oral Science Inc., a dental hygiene product distributor based in Quebec.](https://longbridge.com/zh-CN/news/277476770.md)
*2026-03-02T13:32:35.000Z*
> On March 2, 2026, in Mississauga, Ontario, BioSyent Inc. completed the acquisition of Oral Science Inc., a private Canad

### [Male birth control options in phase II trials offer non-hormonal methods for men beyond condoms and vasectomy.](https://longbridge.com/zh-CN/news/276375511.md)
*2026-02-19T20:24:43.000Z*
> In Los Angeles on February 19, 2026, it was reported that there is a growing demand among men for alternative contracept

### [15:22 ETTwo Male Birth Control Options Advance Into Phase II Clinical Trials](https://longbridge.com/zh-CN/news/276374321.md)
*2026-02-19T20:23:57.000Z*
> NEXT Life Sciences has advanced two male contraceptive options, Plan A™ and NLS-133, into Phase II clinical trials. Plan

### [09:13 ETNotice of Pendency and Proposed Settlement of Stockholder Class Action Involving All Record and Beneficial Holders of CM Life Sciences III, Inc. Class A Common Stock on December 14, 2021](https://longbridge.com/zh-CN/news/275913385.md)
*2026-02-13T14:13:57.000Z*
> Notice of Pendency and Proposed Settlement of Stockholder Class Action for CM Life Sciences III, Inc. Class A Common Sto

### [LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories | BBCMF Stock News](https://longbridge.com/zh-CN/news/275043764.md)
*2026-02-05T15:00:00.000Z*
> LIR Life Sciences Corp. has initiated Project Phase 2 of its peptide design program in collaboration with Neuland Labora

### [Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site](https://longbridge.com/zh-CN/news/273978219.md)
*2026-01-28T10:36:00.000Z*
> Mabtech and Sai Life Sciences have announced a strategic collaboration to enhance immunology research using the EYRA pla

### [StageZero Announces Partial Revocation of Failure to File Cease Trade Order and Proposed Financing](https://longbridge.com/zh-CN/news/273150026.md)
*2026-01-21T00:30:19.000Z*
> StageZero Life Sciences, Ltd. announced a Partial Revocation Order from the Ontario Securities Commission, allowing the